Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  The Lancet

• Publication date

  2002-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(02)08213-2PMID 11955534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adhesion molecules in rheumatoid arthritis

  2004cited by this paper
• Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments

  2001cited by this paper
• Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs?

  2001cited by this paper
• Premature mortality in patients with rheumatoid arthritis: evolving concepts.

  2001cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Damage in systemic lupus erythematosus and its association with corticosteroids.

  2000cited by this paper
• Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes.

  2000cited by this paper
• Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

  2000cited by this paper
• Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.

  2000cited by this paper
• A tale of two diseases: atherosclerosis and rheumatoid arthritis.

  1999cited by this paper
• Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis.

  1999cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.

  1998cited by this paper
• Methotrexate and emerging therapies.

  1998cited by this paper
• Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

  1997cited by this paper
• Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years.

  1997cited by this paper
• Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.

  1994cited by this paper
• The mortality of rheumatoid arthritis.

  1994cited by this paper
• Prediction of Long-Term Mortality in Patients with Rheumatoid Arthritis according to Simple Questionnaire and Joint Count Measures

  1994cited by this paper
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

  1993cited by this paper
• The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

  1993cited by this paper
• Analysis of methotrexate treatment effect in a longitudinal observational study: utility of cluster analysis.

  1991cited by this paper
• Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation.

  1991cited by this paper
• Mortality predictors among 263 patients with rheumatoid arthritis.

  1991cited by this paper
• Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis

  1990cited by this paper
• Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial.

  1990cited by this paper
• Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study.

  1989cited by this paper
• Cardiovascular mortality in patients with rheumatoid arthritis.

  1989cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• Cause of death in rheumatoid arthritis.

  1984cited by this paper
• Measurement of patient outcome in arthritis.

  1980cited by this paper
• Measuring health status in arthritis. The arthritis impact measurement scales.

  1980cited by this paper
• American Rheumatism Association

  1952cited by this paper

• Heart Failure in Rheumatoid Arthritis: Epidemiology, Pathogenesis, Diagnosis, Treatment, and Emerging Insights-A Comprehensive Review.

  2026cites this paper
• The Dynamics of Blood-Count-Derived Inflammatory Indices in the Course of Systemic Treatment for Psoriasis: A Single Center Study

  2026cites this paper
• On the limitations for causal inference in Cox models with time-varying treatment

  2025cites this paper
• Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence

  2025influential citation
• Perioperative management with DMARDs in rheumatic diseases: a scoping review of clinical guidelines

  2025cites this paper
• Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials

  2025cites this paper
• Interleukin-6: A Novel Risk Factor and Therapeutic Target in Coronary Artery Disease

  2025cites this paper
• Low prevalence of methotrexate intolerance in rheumatoid arthritis: a South African study

  2025cites this paper
• Doubly Robust and Efficient Calibration of Prediction Sets for Right-Censored Time-to-Event Outcomes

  2025cites this paper
• Management of Bullous Pemphigoid in Special Populations: A Narrative Review of the Literature

  2025cites this paper
• Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus.

  2025cites this paper
• Metotrexato e leflunomida ainda têm seu lugar no tratamento da artrite reumatoide?

  2025cites this paper
• Dual Targeting Biomimetic Carrier‐Free Nanosystems for Photo‐Chemotherapy of Rheumatoid Arthritis via Macrophage Apoptosis and Re‐Polarization

  2025cites this paper
• Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis.

  2025cites this paper
• Short-term and long-term outcomes in rheumatoid arthritis patients following percutaneous coronary intervention: A systematic review and meta-analysis

  2025cites this paper
• Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study

  2025cites this paper
• Post-Translational Modifications of Lipoproteins: Emerging Players Linking Inflammation and Cardiovascular Disease in Rheumatoid Arthritis—A Narrative Review

  2025cites this paper
• Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: A scoping review.

  2024cites this paper
• Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart

  2024cites this paper
• Causality for Functional Longitudinal Data

  2024cites this paper
• Patient questionnaires for clinical decisions at the point of care, in addition to research reports, an intellectual and ethical opportunity for rheumatologists: A tribute to Frederick Wolfe, MD (July 1, 1936 - September 5, 2023).

  2024cites this paper
• Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study

  2024cites this paper
• Treating Cardiovascular Disease in the Inflammatory Setting of Rheumatoid Arthritis: An Ongoing Challenge

  2024cites this paper
• [Low-dose methotrexate: Indications and side effects, particularly in cases of diffuse interstitial pneumonia].

  2024cites this paper
• The impact of the human gut microbiome on the treatment of autoimmune disease

  2024cites this paper
• 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs

  2024cites this paper
• Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary

  2024cites this paper
• Incremental Causal Effect for Time to Treatment Initialization

  2024cites this paper
• Untargeted metabolic profiling of high-dose methotrexate toxicity shows alteration in betaine metabolism

  2024cites this paper
• Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management

  2024cites this paper
• The Emerging Specialty of Cardio-Rheumatology

  2024cites this paper
• Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).

  2023cites this paper
• TAp63, a methotrexate target in CD4+ T cells, suppresses Foxp3 expression and exacerbates autoimmune arthritis

  2023cites this paper
• La artritis reumatoide

  2023cites this paper
• Methotrexate & Rheumatoid Arthritis Associated Atherosclerosis: A Narrative Review of Multidisciplinary Approach for Risk Modification by the International Board of Experts.

  2023cites this paper
• Kardiovaskuläre Komorbidität bei Psoriasis – Entzündung in Psoriasis betrifft nicht nur die Haut

  2023cites this paper
• Penetration enhancer containing vesicles for dermal and transdermal drug delivery. A review.

  2023cites this paper
• Cardiovascular comorbidity in psoriasis – psoriatic inflammation is more than just skin deep

  2023cites this paper
• Engineered mesenchymal stem cell-derived extracellular vesicles constitute a versatile platform for targeted drug delivery.

  2023cites this paper
• The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review

  2023cites this paper
• Mortality estimates and excess mortality in rheumatoid arthritis

  2023cites this paper
• Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study

  2023cites this paper
• Cardiac magnetic resonance assessment of cardiac involvement in autoimmune diseases

  2023cites this paper
• The Cardiovascular Burden of Rheumatoid Arthritis - Implications for Treatment.

  2023cites this paper
• Genome‐Wide Assessment of Shared Genetic Architecture Between Rheumatoid Arthritis and Cardiovascular Diseases

  2023cites this paper
• Role of Albumin as a Targeted Drug Carrier in the Management of Rheumatoid Arthritis: A Comprehensive Review.

  2023cites this paper
• Anti-inflammatory therapy in atherosclerotic cardiovascular disease: Current reappraisal

  2023cites this paper
• Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?

  2023cites this paper
• Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study.

  2023cites this paper
• The management of cardiovascular disease risk in patients with rheumatoid arthritis

  2022cites this paper
• Managing Cardiovascular Risk in Patients with Rheumatic Disease.

  2022cites this paper
• Visual Outcomes of Patients With Peripheral Ulcerative Keratitis and the Effect of Immunosuppression—A 6-Year Experience in Queensland, Australia

  2022cites this paper
• Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions.

  2022cites this paper
• Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation.

  2022cites this paper
• Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease

  2022cites this paper
• Anti-inflammatory strategies for atherosclerotic artery disease

  2022cites this paper
• Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

  2022cites this paper
• Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis

  2022cites this paper
• Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review.

  2022cites this paper
• Correlation between chronic inflammation of rheumatoid arthritis and coronary lesions: “About a monocentric series of 202 cases”

  2022cites this paper
• An Integrative Pharmacology Model for Decoding the Underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid Arthritis

  2022cites this paper
• Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities

  2022cites this paper
• Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis

  2022cites this paper
• BTT_A_364191 187..197

  2022cites this paper
• Health disparities in rheumatoid arthritis

  2022cites this paper
• Vascular Age, Metabolic Panel, Cardiovascular Risk and Inflammaging in Patients With Rheumatoid Arthritis Compared With Patients With Osteoarthritis

  2022cites this paper
• Hydroxychloroquine: Heart-Throb No More?

  2022cites this paper
• Hotspots and future directions in rheumatoid arthritis-related cardiovascular disease: A scientometric and visualization study from 2001 to 2021 based on Web of Science

  2022cites this paper
• Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases

  2022cites this paper
• Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in Patients With Rheumatoid Arthritis

  2022cites this paper
• Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy

  2022cites this paper
• Cardio-Rheumatology: Prevention of Cardiovascular Disease in Inflammatory Disorders.

  2022cites this paper
• Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies.

  2022cites this paper
• The correlation between cardiovascular risk and functional The correlation between cardiovascular risk and functional disability and disease activity in the patients with rheumatoid disability and disease activity in the patients with rheumatoid arthritis arthritis

  2022cites this paper
• Incidence of New Carotid Plaques in Rheumatoid Arthritis Patients: Six Years Prospective Results of the TOMORROW Study.

  2022cites this paper
• Mechanisms of vascular damage in systemic lupus erythematosus

  2021cites this paper
• Cardiovascular Diseases and Rheumatology

  2021cites this paper
• Proximal Causal Learning with Kernels: Two-Stage Estimation and Moment Restriction

  2021cites this paper
• Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs

  2021cites this paper
• Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

  2021cites this paper
• Introduction to Time-dependent Confounders and Marginal Structural Models

  2021cites this paper
• Methotrexate and Cardiovascular Disease in Patients With Rheumatoid Arthritis: Insights and Novel Speculations

  2021cites this paper
• Arterial wall inflammation in rheumatoid arthritis is reduced by anti-inflammatory treatment.

  2021cites this paper
• Cardiovascular effects of approved drugs for rheumatoid arthritis

  2021cites this paper
• Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis

  2021cites this paper
• Managing Cardiovascular Risk in Patients with Rheumatic Disease.

  2021influential citation
• Evaluation of prescription practices in rheumatoid arthritis at the rheumatology clinic in a tertiary care teaching hospital in Uttarakhand: A cross-sectional study

  2021cites this paper
• Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation

  2021cites this paper
• The case of methotrexate and the lung: Dr Jekyll and Mr Hyde

  2021cites this paper
• Theoretical evidence explaining the relationship between socio-demographic and psychosocial barriers on access to oral health care among adults: A scoping review.

  2021cites this paper
• Formulation and Characterization of Alginate-Based Membranes for the Potential Transdermal Delivery of Methotrexate

  2021cites this paper
• Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk

  2021cites this paper
• Long-term remission and biologic persistence rates: 12-year real-world data

  2021cites this paper
• Excess mortality persists in patients with rheumatoid arthritis

  2021cites this paper
• Kardiale Beteiligungen bei rheumatologischen Erkrankungen – eine Übersicht

  2021cites this paper
• Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?

  2021cites this paper
• The impact of diabetes mellitus on treatment and outcomes of rheumatoid arthritis at 5-year follow-up: results from a multi-ethnic Asian cohort

  2021cites this paper
• The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights

  2021cites this paper
• Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment

  2021cites this paper
• Evaluation of the effect of methotrexate on the hippocampus, cerebellum, liver, and kidneys of adult male albino rat: Histopathological, immunohistochemical and biochemical studies.

  2021cites this paper